Ovarian cancer is one of the common tumors of the female reproductive organs. Its incidence is second only to cervical cancer and corpus uteri cancer, ranking third, but the mortality rate due to ovarian cancer accounts for the first place among all gynecological tumors, posing a serious threat to women's lives. Due to the complex embryonic development, tissue anatomy, and endocrine function of the ovary, the tumors it may have can be benign or malignant. Because ovarian cancer has no symptoms in the early stage, it is quite difficult to differentiate its tissue type and benign or malignant nature. Only 30% of ovarian cancer tumors are found to be localized to the ovary during exploratory laparotomy, while the majority have spread to the uterus, bilateral adnexa, omentum, and various organs in the pelvis. Therefore, ovarian cancer is indeed a major challenge in both diagnosis and treatment. For many years, experts have conducted many discussions on the pathological morphology, clinical occurrence and development patterns, and treatment plans for ovarian malignant tumors, accumulating a large amount of experience. So far, according to the clinical data statistics outside of China, the five-year survival rate is only 25% to 30%.